Skip to main content
    K

    Karyopharm Therapeutics Inc (KPTI)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.02
    -0.02 (-56.50%)

    Market Cap: $394,660

    Last updated: Nov 10, 2026 at 7:59 PM ET

    Karyopharm Therapeutics Inc (KPTI) Stock Forecast

    Updated Nov 10, 2026. Estimates and ratings come from consensus analyst data.

    Analysts expect Karyopharm Therapeutics (KPTI) to earn -$5.68 per share in the fiscal year ending Dec 31, 2026, on revenue of $135.22M. Of 5 analysts, 4 rate the stock Buy or Strong Buy, 1 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 1 estimate for the fiscal year ending Dec 31, 2026 was revised up and 1 down.

    Analyst Ratings

    Scoring Strong Buy as 1 and Strong Sell as 5, the 5 ratings average 1.80, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 80% of the ratings.

    RatingAnalystsShare
    Strong Buy240.0%
    Buy240.0%
    Hold120.0%
    Sell00.0%
    Strong Sell00.0%
    Consensus
    Buy
    Total analysts
    5

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Annual Estimates

    From the first fiscal year below to the second, the EPS consensus shows a smaller loss and revenue estimates rise 27.7%.

    Fiscal year ending Dec 31, 2026
    -$5.68
    EPS consensus, revenue $135.22M
    Fiscal year ending Dec 31, 2027
    -$1.92
    EPS consensus, revenue $172.74M
    Next report
    Feb 10, 2027
    Estimated

    EPS range

    Revenue range

    Fiscal year endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026-$5.68-$5.68 to -$5.681$135.22M$130.93M to $137.72M4
    Dec 31, 2027-$1.92-$1.92 to -$1.921$172.74M$155.79M to $198.43M3

    Quarterly Estimates

    Quarter endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026-$0.62-$0.83 to -$0.335$34.65M$32.49M to $37.03M5

    Estimate Revisions

    Across the 2 periods below, the last 30 days brought 3 upward and 1 downward EPS revisions.

    PeriodUp 30 daysDown 30 days
    Fiscal year ending Dec 31, 202611
    Fiscal year ending Dec 31, 202720

    EPS Trend

    Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has worsened from -$4.76.

    PeriodNow7 days ago30 days ago60 days ago90 days agoChange
    Fiscal year ending Dec 31, 2026-$5.68-$5.85-$5.85-$5.85-$4.76N/A
    Fiscal year ending Dec 31, 2027-$1.92-$2.82-$2.82-$2.82-$3.21N/A

    Frequently Asked Questions About KPTI

    What is the KPTI stock forecast?

    Consensus analyst estimates put Karyopharm Therapeutics's EPS at -$5.68 for the fiscal year ending Dec 31, 2026, on revenue of $135.22M. The consensus rating from 5 analysts is Buy.

    How do analysts rate KPTI stock?

    Of 5 analysts covering Karyopharm Therapeutics, 2 rate it Strong Buy, 2 Buy, 1 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.

    What EPS do analysts expect from KPTI next year?

    For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$5.68, with estimates from -$5.68 to -$5.68 from 1 analyst. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$1.92, with estimates from -$1.92 to -$1.92 from 1 analyst.

    What revenue do analysts expect from Karyopharm Therapeutics next year?

    For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $135.22M, with estimates from $130.93M to $137.72M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $172.74M, with estimates from $155.79M to $198.43M.

    How many analysts cover KPTI?

    5 analysts rate Karyopharm Therapeutics stock, and 1 analyst estimates its EPS for the fiscal year ending Dec 31, 2026.